Atara Biotherapeutics (NASDAQ: ATRA)
Atara Biotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Atara Biotherapeutics Company Info
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
News & Analysis
Why Atara Biotherapeutics Stock Is Crashing Today
Investors were hoping for more from the company's latest clinical update.
Why Atara Biotherapeutics Stock Is Sinking Today
A fatality in an early-stage clinical trial is weighing on the cell therapy company's stock today.
2 Steps to Biotech Success: Good Data, Then Raise Capital
Companies that don't do the second step won't last long in this industry.
2 Biotech Stocks That Could Soar in 2020
These companies offer promising pipelines that could deliver in the long term.
2 Top Biotech Stocks Under $10
Amarin and Atara Biotherapeutics could both be diamonds in the rough.
2 Incredibly Cheap Cancer Stocks to Buy Now
These two cancer stocks are trading at a pittance compared to their long-term value propositions.
Why Atara Biotherapeutics Has Slumped in 2019
Atara's shares have collapsed this year. Here's why.
Why Atara Biotherapeutics Stock Is Imploding Today
Investors are growing impatient with this clinical-stage biotech.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.